Wolf v. Altmann

District Court, E.D. Missouri·Decided December 16, 2022·No. 4:22-cv-00397·Unknown

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF MISSOURI EASTERN DIVISION

MATTHEW D. WOLF, ) ) Plaintiff/Counter-Defendant, ) ) v. ) No. 4:22-CV-397 PLC ) DANIEL ALTMANN, ) ) Defendant/Counter-Claimant, ) ) and ) ) BOTANNIS LABS MO. CORP. INC., ) ) Counter-Claimant. )

MEMORANDUM AND ORDER

Matthew Wolf, an indirect minority shareholder of Counter-Claimant Botannis Labs Mo. Corp. Inc. (Botannis) filed a complaint against Defendant/Counter-Claimant Daniel Altmann (Altmann) seeking a declaratory judgment clarifying his legal obligations to fund the business operations and perform work on behalf of Botannis. [ECF No. 1] Altmann and Botannis filed a counterclaim against Wolf, alleging breach of fiduciary and fraud. [ECF No. 21] Wolf moved to dismiss the counterclaim. [ECF No. 31] In response to Wolf’s motion to dismiss, Altmann and Botannis filed a three-count first amended counterclaim asserting breach of fiduciary duty, fraud, and negligent misrepresentation. [ECF No. 35] Wolf thereafter filed (1) a motion to dismiss Altmann’s claims in the first amended counterclaim pursuant to Federal Rules of Civil Procedure 9(b), 12(b)(6), and 23.1 and (2) a motion to stay discovery pending adjudication of Altmann’s counterclaims. [ECF No. 37, 43] The Court considers below Wolf’s motions to dismiss and motion to stay discovery. I. Background1 Wolf is a Colorado-based businessman with experience in the legal cannabis industry. [ECF No. 1 at ¶ 13] After Missouri voters approved an amendment to the Missouri Constitution legalizing medical marijuana in the state, Wolf sought business opportunities in Missouri. [Id. at ¶ 8] Missouri, however, requires medical-marijuana businesses to be majority-owned by Missouri citizens. [Id. at ¶ 9] Wolf was introduced to Jeffrey Altmann (Jeffrey) and they discussed opening a medical- marijuana business in Missouri, with Wolf “contributing his expertise to the venture” and Jeffrey satisfying the residency requirement and navigating the regulatory process. [Id. at ¶¶14, 16] Wolf and Jeffrey agreed to apply for a license for a testing laboratory in Missouri. [Id. at ¶ 17, ECF No. 35 at ¶ 19] In the amended counterclaim, Altmann alleges that on July 20, 2019, Wolf made a $1,000,000 written commitment to fund the business, specifically promising: “Funding Commitment: $200k at close[,] $300k at licensing, and $500k at first revenue.”2 [ECF No. 35, ¶¶

1 In assessing the adequacy of a complaint under Rule 12(b)(6), the Court generally ignores materials outside of the pleadings. Ashford v. Douglas Cty., 880 F.3d 990, 992 (8th Cir. 2018). The Court, however, may consider materials that are part of the public record or do not contradict the complaint, as well as materials that are necessarily embraced by the pleadings. Id. 2 Altmann does not state the source of this written commitment and did not attach a copy of the document to the first amended counterclaim. Wolf, however, alleged in his complaint that he sent an email to Jeffrey on July 20, 2019, and attached the purported email to his complaint. [ECF No. 1 at ¶¶ 71-77] This documents states, in relevant part:

Jeff, For discussion. Botannis Labs MO Corp. 51% Jeffrey Altmann, President 49% Matt Wolf, CEO

Funding Commitment: $200k at close $300k at licensing $500k at first revenue

The email then sets forth a list of items and services with amounts and states: 2 22-23] Altmann alleges Wolf did not state that the funding commitment was speculative or contingent on any future event provided that the company obtained a testing license. [ECF No. 35 at ¶ 26] On July 25, 2019, Jeffery filed Articles of Incorporation with the Missouri Secretary of State formally incorporating the company, Botannis. [ECF No. 35 at ¶ 29, ECF No. 1 at ¶ 23, ECF No. 35-11] On July 29, 2019, Jeffrey and Wolf decided that Altmann would replace Jeffrey “as an owner in Botannis due to uncertainty surrounding Jeffrey’s eligibility [to obtain a marijuana testing license] under state law.” [ECF No. 1 at ¶ 21, ECF No. 35 at ¶ 30] Altmann alleges that he “agreed to be an owner in Botannis based on representations made by Wolf regarding his funding commitments, revenue forecasts, business acumen, and Wolf’s general expertise in the marijuana industry.” [ECF No. 35 at ¶ 32] During a meeting in July 2019, Altmann agreed to be President of Botannis and Jeffery, on Altmann’s behalf, agreed to obtain the testing license, ensure compliance with state laws and regulations, and to procure “clients.” [ECF No. 35 at ¶ 35] Altmann alleges that, during this meeting, Wolf agreed to: (1) “the Funding Commitment” “if they obtained a license because that amount of money was needed to get Botannis up and running[;]” (2) provide the knowledge necessary to conduct the testing permitted under the license; and (3) provide “hundreds of thousands of dollars” in necessary “testing equipment” through his “procurement department[.]” [ECF No. 35 at ¶ 35]

Revenue ~$1M

COGS $500k SGA $500k

Our goal is a break-even business supporting important infrastructure and payroll.

[ECF No. 1-1, Ex. H] 3 In August 2019, Jeffrey executed a “consent in lieu of meeting of sole incorporator” in which he adopted bylaws for Botannis;3 fixed the number of corporate directors at two; elected Wolf and Altmann as the directors; and resigned as the sole incorporator. [ECF No. 35-2] Ultimately, Altmann acquired 51% ownership interest in Botannis; BLMO, Inc., an organization wholly owned by Wolf, acquired 43% ownership; and three New York residents, Nicholas Kingsbury, Kevin Nguyen, and Ann Costanza, each acquired 2% ownership.4 [ECF No. 1 at ¶¶ 23, 28; ECF No. 35 at ¶ 39] Altmann alleges, on information and belief, that Kingsbury, Nguyen, and Costanza “are social acquaintances or colleagues of Wolf and work with Wolf[.]” [ECF No. 35 at ¶ 59] On August 17, 2019, Botannis applied for a marijuana testing license with Missouri. [ECF No. 1 at ¶ 28; ECF No. 35 at ¶ 48] Because the license application required Botannis to provide evidence of adequate capitalization, Botannis’ application included a statement that “Our Testing Facility team has $400,000.00 in liquid capital deposited with financial institutions under the name of Owner/CEO Matthew D. Wolf, …that has been pledged to the Botannis Testing Facility[.]” [ECF No. 1 at ¶ 29; ECF No. 35-6] Attached to the application was a bank account statement in Wolf’s name, and Wolf’s August 16, 2019 affidavit averring and “acknowledging my grant of a revocable pledge of $400,000.00 to Botannis Labs Mo Corp. for the purposes of successfully carrying out the activities described in the application.” [ECF No. 35-6] Altmann alleges Wolf “explained to [Altmann] and Jeffrey that [the $400,000 ‘revocable’ pledge] simply meant that if Botannis did not receive a license Wolf would take back the $400,000[.]” [ECF No. 35 at ¶ 63] Altmann also alleges that “Wolf submitted a five (5) year annual profit and [loss] forecast” under which Wolf estimated annual “gross profits” ranging from

Free access — add to your briefcase to read the full text and ask questions with AI

Wolf v. Altmann, (E.D. Mo. 2022).

Wolf v. Altmann (Wolf v. Altmann) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Cole v. Homier Distributing Co., Inc.
599 F.3d 856 (Eighth Circuit, 2010)
Warth v. Seldin
422 U.S. 490 (Supreme Court, 1975)
Swierkiewicz v. Sorema N. A.
534 U.S. 506 (Supreme Court, 2002)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Rothenberg v. Security Management Co.
667 F.2d 958 (Eleventh Circuit, 1982)
Larson v. Dumke
900 F.2d 1363 (Ninth Circuit, 1990)
Crest Construction II, Inc. v. Doe
660 F.3d 346 (Eighth Circuit, 2011)
Polytech, Inc. v. Affiliated Fm Insurance Company
21 F.3d 271 (Eighth Circuit, 1994)
Rhonda S. Kunferman v. Ford Motor Company
112 F.3d 962 (Eighth Circuit, 1997)
Vess v. Ciba-Geigy Corp. USA
317 F.3d 1097 (Ninth Circuit, 2003)